Synapse
Click here to find out more
COVID-19 postponement of MDR implementation date – how does this fit with Brexit?
26 May 2020
IN-DEPTH ANALYSIS
Coronavirus
Click here to find out more
What you need to know about the UK Government's new Future Fund 2.0
19 May 2020
IN-DEPTH ANALYSIS
by multiple authors
Environmental, planning & regulatory
Click here to find out more
Hope for compensation for Corona-related plant closures increases
15 May 2020
Life sciences & healthcare
Click here to find out more
Everything biologic and biosimilar in-house counsel need to know about COVID-19
29 April 2020
by multiple authors
Coronavirus
Click here to find out more
What you need to know about the UK government's new Future Fund
27 April 2020
IN-DEPTH ANALYSIS
by multiple authors
Synapse
Click here to find out more
Patent pools: an easy licensing option for COVID-19 drugs and SARS CoV 2 vaccines?
22 April 2020
IN-DEPTH ANALYSIS
Life sciences & healthcare
Click here to find out more
Termination, force majeure and frustration – international perspectives on the life sciences sector
17 April 2020
QUICK READ
by multiple authors
Patents & innovation
Click here to find out more
COVID-19 and public compulsory licensing of drugs in Europe
17 April 2020
IN-DEPTH ANALYSIS
by multiple authors
Synapse
Click here to find out more
COVID-19 and life sciences M&A
16 April 2020
IN-DEPTH ANALYSIS
by multiple authors
Patents & innovation
Click here to find out more
Marketing authorisation and clinical testing of new drugs
15 April 2020
Patents & innovation
Click here to find out more
Restrictions for patents owners to preserve the public interest in the sufficient availability of necessary medicinal products
7 April 2020